Zentalis Pharmaceuticals (ZNTL) Invested Capital (2022 - 2025)
Historic Invested Capital for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $252.9 million.
- Zentalis Pharmaceuticals' Invested Capital fell 2863.34% to $252.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.9 million, marking a year-over-year decrease of 2863.34%. This contributed to the annual value of $337.2 million for FY2024, which is 2290.97% down from last year.
- As of Q3 2025, Zentalis Pharmaceuticals' Invested Capital stood at $252.9 million, which was down 2863.34% from $274.5 million recorded in Q2 2025.
- Zentalis Pharmaceuticals' Invested Capital's 5-year high stood at $523.3 million during Q2 2023, with a 5-year trough of $252.9 million in Q3 2025.
- Moreover, its 4-year median value for Invested Capital was $385.7 million (2023), whereas its average is $389.0 million.
- Per our database at Business Quant, Zentalis Pharmaceuticals' Invested Capital skyrocketed by 2217.5% in 2023 and then crashed by 3561.45% in 2025.
- Over the past 4 years, Zentalis Pharmaceuticals' Invested Capital (Quarter) stood at $434.0 million in 2022, then rose by 0.78% to $437.4 million in 2023, then decreased by 22.91% to $337.2 million in 2024, then decreased by 25.0% to $252.9 million in 2025.
- Its Invested Capital was $252.9 million in Q3 2025, compared to $274.5 million in Q2 2025 and $295.4 million in Q1 2025.